China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
Laekna, Inc. Advances LAE123 for Severe Diseases
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At ...
Business Wire10d
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obe…
Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...
Laekna, Inc. Announces Share Placement to Raise HK$230 Million
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...
U.S. News & World Report10d
China-Based Biotech Laekna Teams up With Lilly to Develop Muscle Preserving Obesity Drug
(Reuters) - Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on ...
Nasdaq10d
Laekna Partners with Eli Lilly on Obesity Drug Development
This partnership will see Lilly funding and executing a phase I study in the U.S., while Laekna retains global rights to the monoclonal antibody that targets muscle regeneration and lipid metabolism.
Yahoo Finance10d
Laekna, Inc. (2105.HK)
LOS ANGELES, November 20, 2024--Laekna, Inc. (2105.HK) ("Laekna"), a global biotech company focused on novel drug development for metabolic and cancer diseases, is pleased to announce a clinical ...
Yahoo Finance17d
Laekna, Inc. (2105.HK)
Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the ...
Wall Street Journal1y
Laekna Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...